Related Experiment Video

Updated: Jun 16, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Jiahuai Tan1, Shundong Cang, Yuehua Ma

  • 1Department of Medicine, The Mount Vernon Hospital, Mount Vernon, NY 10550, USA.

Journal of Hematology & Oncology
|February 6, 2010
PubMed

Insights

Histone deacetylase (HDAC) inhibitors show promise in cancer treatment by regulating gene expression. Clinical trials are exploring their efficacy in various hematological and solid malignancies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) regulate gene expression and chromatin structure, impacting cancer initiation and progression.
  • Gene repression via acetylation modulation is a validated therapeutic strategy in cancer.
  • Vorinostat, an HDAC inhibitor, is FDA-approved for cutaneous T-cell lymphoma (CTCL).

Purpose of the Study:

  • To review recent developments in clinical trials of HDAC inhibitors as anti-tumor agents.
  • To highlight the therapeutic potential of various HDAC inhibitors in different malignancies.

Main Methods:

  • Review of current clinical trials involving HDAC inhibitors.
  • Analysis of therapeutic potential of HDAC inhibitors as monotherapy or in combination treatments.

Main Results:

  • Multiple HDAC inhibitors (e.g., FK228, PXD101, MS-275) demonstrate therapeutic potential.
  • Over 80 clinical trials are investigating HDAC inhibitors for hematological and solid tumors.

Conclusions:

  • HDAC inhibitors represent a promising class of anti-cancer agents.
  • Ongoing clinical trials are crucial for evaluating the efficacy of HDAC inhibitors in diverse cancer types.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...